Prothena Co. plc (NASDAQ:PRTA - Get Free Report)'s share price reached a new 52-week low on Friday . The company traded as low as $15.22 and last traded at $15.24, with a volume of 84680 shares changing hands. The stock had previously closed at $16.10.
Analyst Upgrades and Downgrades
Several research firms have recently commented on PRTA. Royal Bank of Canada decreased their target price on shares of Prothena from $28.00 to $24.00 and set a "sector perform" rating for the company in a research report on Friday, August 9th. Oppenheimer lowered their price objective on Prothena from $66.00 to $62.00 and set an "outperform" rating for the company in a research note on Wednesday, August 14th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Prothena in a research report on Monday, September 30th. StockNews.com raised Prothena from a "sell" rating to a "hold" rating in a research report on Monday, August 12th. Finally, HC Wainwright restated a "buy" rating and set a $84.00 price objective on shares of Prothena in a research note on Wednesday. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, Prothena presently has an average rating of "Moderate Buy" and an average price target of $61.86.
Get Our Latest Stock Report on Prothena
Prothena Stock Performance
The stock has a market cap of $753.86 million, a P/E ratio of -5.65 and a beta of 0.16. The business has a 50 day simple moving average of $18.19 and a 200-day simple moving average of $20.34.
Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported ($1.10) earnings per share for the quarter, beating the consensus estimate of ($1.18) by $0.08. The company had revenue of $0.97 million during the quarter, compared to analyst estimates of $1.22 million. Prothena had a negative net margin of 98.86% and a negative return on equity of 24.19%. The firm's revenue for the quarter was down 98.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.38 earnings per share. On average, sell-side analysts predict that Prothena Co. plc will post -2.34 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Prothena
Institutional investors have recently bought and sold shares of the company. DCF Advisers LLC raised its stake in shares of Prothena by 0.5% in the second quarter. DCF Advisers LLC now owns 107,500 shares of the biotechnology company's stock valued at $2,219,000 after buying an additional 500 shares during the period. Orion Portfolio Solutions LLC raised its stake in Prothena by 4.4% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 17,531 shares of the biotechnology company's stock valued at $293,000 after acquiring an additional 739 shares during the period. Signaturefd LLC lifted its holdings in Prothena by 182.1% during the second quarter. Signaturefd LLC now owns 1,337 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 863 shares during the last quarter. ProShare Advisors LLC boosted its position in Prothena by 8.9% during the first quarter. ProShare Advisors LLC now owns 11,346 shares of the biotechnology company's stock worth $281,000 after purchasing an additional 932 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Prothena by 13.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,236 shares of the biotechnology company's stock worth $211,000 after purchasing an additional 1,186 shares in the last quarter. Hedge funds and other institutional investors own 97.08% of the company's stock.
About Prothena
(
Get Free Report)
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.
Read More
Before you consider Prothena, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prothena wasn't on the list.
While Prothena currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
